UBS Downgrades ResMed to Neutral, Lowers Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Saul Hadassin has downgraded ResMed (NYSE:RMD) from Buy to Neutral and lowered the price target from $265 to $170.
September 05, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed's stock rating has been downgraded from Buy to Neutral by UBS, with a lowered price target from $265 to $170.
The downgrade from Buy to Neutral by UBS indicates a less optimistic outlook for ResMed's stock. The lowered price target from $265 to $170 suggests that UBS expects the stock's price to decrease in the short term. This could potentially lead to a decrease in ResMed's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100